Corcept Therapeutics Inc. (CORT)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$1.36 (+2.29%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Corcept Therapeutics Inc. (CORT)
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Key Insights

Critical company metrics and information
  • Share Price

    $60.78
  • Market Cap

    $6.37 Billion
  • Total Outstanding Shares

    104.78 Million Shares
  • Total Employees

    352
  • Dividend

    No dividend
  • IPO Date

    April 14, 2004
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.corcept.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$144.65 Million
Net Cash Flow From Investing Activities, Continuing$-96.15 Million
Net Cash Flow$25.49 Million
Net Cash Flow From Financing Activities, Continuing$-23.02 Million
Net Cash Flow, Continuing$25.49 Million
Net Cash Flow From Operating Activities$144.65 Million
Net Cash Flow From Investing Activities$-96.15 Million
Net Cash Flow From Financing Activities$-23.02 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Benefits Costs and Expenses$462.21 Million
Basic Earnings Per Share$1.36
Diluted Earnings Per Share$1.26
Income/Loss From Continuing Operations After Tax$141.82 Million
Revenues$628.55 Million
Operating Income/Loss$143.36 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$735000.00
Net Income/Loss$141.82 Million
Net Income/Loss Attributable To Parent$141.82 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Preferred Stock Dividends And Other Adjustments$735000.00
Net Income/Loss Available To Common Stockholders, Basic$140.47 Million
Income Tax Expense/Benefit$24.52 Million
Nonoperating Income/Loss$22.98 Million
Income Tax Expense/Benefit, Deferred$-40.01 Million
Operating Expenses$475.39 Million
Cost Of Revenue$9.80 Million
Costs And Expenses$485.20 Million
Income/Loss From Continuing Operations Before Tax$166.34 Million
Basic Average Shares$308.91 Million
Diluted Average Shares$334.57 Million
Gross Profit$618.75 Million
Research and Development$231.29 Million
Selling, General, and Administrative Expenses$244.10 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Noncurrent Liabilities$19.21 Million
Equity Attributable To Parent$638.84 Million
Current Assets$466.98 Million
Liabilities$145.42 Million
Prepaid Expenses$5.82 Million
Assets$784.26 Million
Liabilities And Equity$784.26 Million
Accounts Payable$18.58 Million
Equity$638.84 Million
Other Current Liabilities$107.63 Million
Noncurrent Assets$317.28 Million
Current Liabilities$126.22 Million
Other Non-current Assets$314.35 Million
Equity Attributable To Noncontrolling Interest$0.00
Fixed Assets$2.93 Million
Inventory$8.05 Million
Other Current Assets$453.11 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.